多组组分析显示,BRI3BP表达升高与肝细胞癌进展和不良预后相关
Ling Liu1,2, Ye Wang2, Jintao Zheng2
1Department of Hepatobiliary and Pancreatic Surgery, Hangzhou First People's Hospital Affiliated to Medical School of Westlake University, No.261 Huansha Road, Shangcheng District, Hangzhou, 310006, Zhejiang, China.
Scientific reports
|November 1, 2025
概括
在肝细胞癌 (HCC) 中,RNA结合蛋白BRI3BP过度表达,与侵袭性瘤和患者生存率差相关. 这表明BRI3BP是HCC的潜在预后生物标志物和治疗标.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 基因组学就是基因组学.
背景情况:
- 肝细胞癌 (HCC) 仍然是一个重大的全球健康挑战,有效生物标志物有限.
- RNA结合蛋白BRI3BP在HCC病原和进展中的作用目前尚未确定.
研究的目的:
- 研究BRI3BP在肝细胞癌中的诊断和预后价值.
- 阐明BRI3BP在HCC进展中的作用和与瘤微环境的关联的分子机制.
主要方法:
- 多主题数据分析 (TCGA,GEO),包括基因组和表观遗传学分析.
- 使用ssGSEA和TIMER 2.0.0进行免疫透分析.
- 在体外功能测定 (细胞迁移,入侵,信号通路分析) 和药物敏感性测试.
主要成果:
- 在HCC中,BRI3BP显著过度表达,与晚期瘤阶段,较短的总生存期 (OS) 和无病生存期 (DFS) 相相关.
- BRI3BP表达与细胞循环调节,Rho GTPase活性,铜恒常性和免疫抑制性瘤微环境与改变的免疫细胞透有关.
- 在体外BRI3BP的过度表达促进HCC细胞迁移和入侵,激活ROCK信号通路,并与对lapatinib的敏感性增加有关.
结论:
- 高BRI3BP表达与攻击性HCC表型,预后不佳和瘤性途径的激活有关.
- BRI3BP作为一种潜在的预后生物标志物和肝细胞癌的候选治疗标.
相关概念视频
02:23Abnormal Proliferation
5.1K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.1K
01:22PI3K/mTOR/AKT Signaling Pathway
5.3K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
5.3K